Mink Therapeutics Stock Target Price
| INKT Stock | USD 0.73 0.01 1.39% |
Mink Therapeutics fundamentals help investors to digest information that contributes to Mink Therapeutics' financial success or failures. It also enables traders to predict the movement of Mink Stock. The fundamental analysis module provides a way to measure Mink Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mink Therapeutics stock.
Mink | Target Price |
Mink Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mink Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mink Therapeutics could also be used in its relative valuation, which is a method of valuing Mink Therapeutics by comparing valuation metrics of similar companies.Mink Therapeutics is currently under evaluation in target price category among its peers.
Mink Fundamentals
| Return On Equity | -12.39 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 27.26 M | ||||
| Shares Outstanding | 39.55 M | ||||
| Shares Owned By Insiders | 74.64 % | ||||
| Shares Owned By Institutions | 2.25 % | ||||
| Number Of Shares Shorted | 50.69 K | ||||
| Price To Book | 10.05 X | ||||
| EBITDA | (22.25 M) | ||||
| Net Income | (22.46 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.88 X | ||||
| Total Debt | 22.61 M | ||||
| Current Ratio | 1.74 X | ||||
| Book Value Per Share | (0.52) X | ||||
| Cash Flow From Operations | (15.76 M) | ||||
| Short Ratio | 1.10 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Target Price | 6.67 | ||||
| Number Of Employees | 31 | ||||
| Beta | 0.048 | ||||
| Market Capitalization | 28.97 M | ||||
| Total Asset | 4.55 M | ||||
| Retained Earnings | (133.4 M) | ||||
| Working Capital | (7.8 M) | ||||
| Net Asset | 4.55 M |
About Mink Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mink Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mink Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mink Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.